FDA Approves Wegovy for Treatment of Serious Liver Disease

The U.S. Food and Drug Administration (FDA) has officially approved Wegovy, a medication developed by Novo Nordisk primarily for weight management, for use in treating a serious liver condition known as metabolic dysfunction-associated steatohepatitis (MASH). This approval marks a significant advancement, as Wegovy is now the only GLP-1 receptor agonist authorized to target this type of liver disease. MASH, previously called non-alcoholic steatohepatitis (NASH), involves fat accumulation in the liver leading to inflammation, scarring, and potentially progressing to liver failure or cancer if not properly managed.

Approximately 14.9 million adults in the United States, about 6% of the population, are affected by MASH. The FDA's decision was backed by results from a late-stage clinical trial demonstrating Wegovy's efficacy in treating this condition. This approval not only highlights Wegovy's role in managing liver health but also broadens its therapeutic profile, which already includes weight loss and cardiovascular benefits. In fact, Wegovy's sister drug, Ozempic, which contains the same active ingredient, is approved for diabetes management.

Dr. Martin Holst Lange, Novo Nordisk's chief scientific officer, emphasized the drug’s unique position as the first and only GLP-1 treatment approved for MASH. The approval also opens the door for the drug to be used in Europe and Japan, where similar applications are underway.

While Wegovy is mainly known as a weekly injectable for weight loss, clinical research indicates it may be beneficial for patients with other serious health conditions, including liver disease. The FDA's endorsement reflects a growing recognition of the interconnectedness of weight, metabolic health, and liver health, providing hope for many individuals battling these chronic issues.

For additional information about MASH, refer to the Cleveland Clinic’s resources. This development underscores ongoing progress in addressing complex metabolic and liver disorders, marking a new chapter in treatment options for affected patients.

Source: MedicalXpress